Merck Secures First Oral PCSK9 Inhibitor, Boosts Q1 2026 Earnings and Expands Oncology Pipeline

Merck’s latest triumph—an FDA nod for its first oral PCSK9 inhibitor—comes on the heels of a stronger‑than‑exp...

Read story →